What compounds target BARD1?

BiohacksAI has identified 29 compounds that interact with BARD1 (BRCA1 associated RING domain 1). Top compounds include: Methotrexate, Astemizole Antihistamine drug now withdrawn from, Azacitidine, Azacitidine, Calcimycin. Each compound is ranked by evidence score derived from PubMed bioassay confidence and assay count.

What is BARD1 (BRCA1 associated RING)?

BARD1 is BRCA1 associated RING domain 1. It is a molecular target for 29 compounds documented in PubMed bioassay data. UniProt ID: Q99728. NCBI Gene ID: 580.

BARD1

MOLECULAR TARGET

BRCA1 associated RING domain 1

UniProt: Q99728 NCBI Gene: 58029 compounds

BARD1 (BRCA1 associated RING domain 1) is targeted by 29 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting BARD1

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#	Compound	Confidence	Active Assays
1	Methotrexate	0.69	1
2	Astemizole Antihistamine drug now withdrawn from	0.69	1
3	Azacitidine	0.69	1
4	Azacitidine	0.69	1
5	Calcimycin	0.69	1
6	Chlorhexidine	0.69	1
7	Ciclopirox	0.69	1
8	Colchicine	0.69	1
9	colchine	0.69	1
10	cycloheximide	0.69	1
11	Cytarabine	0.69	1
12	Demecolcine	0.69	1
13	Digitoxigenin 3 beta,14-Dihydroxy-5 beta-card-20(22)enolide.	0.69	1
14	Digoxigenin 3 beta,12 beta,14-Trihydroxy-5 beta-card-20(22)-enolide.	0.69	1
15	dihydrorotenone	0.69	1
16	Fluspirilene	0.69	1
17	gedunin	0.69	1
18	Hexachlorophene	0.69	1
19	lidoflazine	0.69	1
20	Melphalan	0.69	1
21	Niclosamide	0.69	1
22	Nocodazole Nocodazole is	0.69	1
23	paxilline	0.69	1
24	Podophyllotoxin	0.69	1
25	rafoxanide	0.69	1
26	Strophanthidin 3 beta,5,14-Trihydroxy-19-oxo-5 beta-card-20(22)-enolide.	0.69	1
27	Trifluridine	0.69	1
28	Tubercidin	0.69	1
29	vinblastine sulfate	0.69	1

About BARD1 as a Drug Target

BARD1 (BRCA1 associated RING domain 1) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 29 compounds with documented BARD1 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

BARD1 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.